HALO

Business Context and Reporting Period

Company: Halozyme Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: Halozyme is a biopharmaceutical company developing products based on the extracellular matrix, specifically utilizing its proprietary recombinant human PH20 enzyme (rHuPH20). The company has two marketed products: Cumulase (for in vitro fertilization) and Hylenex (an adjuvant for drug delivery). The company operates as a single segment focused on drug delivery, oncology, and dermatology markets.

Key Financial Metrics

Revenue Breakdown (Six Months 2007): Product sales were $356,168; Revenues under collaborative agreements were $1,162,563.
Expense Breakdown (Six Months 2007): Research and Development (R&D) was $6,913,249; Selling, General and Administrative (SG&A) was $4,366,861.

Material Changes vs. Prior Period

• Liquidity Surge: Cash and cash equivalents increased by approximately $56.4 million, driven primarily by financing activities. This contrasts with a cash decrease of $4.0 million in the prior year period.
• Revenue Growth: Total revenues increased by approximately $1.33 million (594% increase) compared to the prior six months. This was driven by the recognition of revenues from new collaborative agreements with Roche and Baxter, which were non-existent in the prior period.
• Operating Loss Expansion: Operating loss increased from $7.1 million to $9.9 million. This was due to a significant increase in operating expenses ($4.15 million increase), primarily in R&D and SG&A, which outpaced revenue growth.
• Financing Activity: The company raised approximately $52.0 million from the issuance of common stock (including a $32.1 million private placement to New River Management V, LP) and proceeds from warrant/option exercises.
• Deferred Revenue: Deferred revenue increased significantly to $30.4 million (including $27.4 million long-term) due to upfront payments received from Roche ($20 million) and Baxter ($10 million) which are being recognized over time.

Guidance, Outlook, and Risks

Management Commentary & Outlook: Management believes current cash resources ($100.6 million) are sufficient to fund operations for at least the next twelve months. The company anticipates significant increases in R&D expenses as it advances its lead oncology candidate, Chemophase, and expands clinical trials. Future funding may be required through equity sales, debt financing, or strategic collaborations.

Key Risks and Contingencies:

• Regulatory Approval: The company has a history of net losses and relies on FDA approval for product candidates (e.g., Chemophase) to generate meaningful revenue. Failure to obtain approval would substantially impair the business.
• Manufacturing Dependence: Halozyme relies on a single contract manufacturer (Avid Bioservices) for its active pharmaceutical ingredient (API) and Baxter for fill/finish of Hylenex. Disruptions at these facilities could halt production.
• Market Acceptance: Even with approval, products face competition from existing hyaluronidase products (e.g., Vitrase, Amphadase) and may face reimbursement challenges.
• Dilution: Future capital raises or the exercise of outstanding warrants (approx. 5.6 million shares) and options (approx. 8.2 million shares) could dilute existing shareholders.

Unusual Items: The company entered into a related-party transaction involving a lease with BC Sorrento, LLC, where a director holds a controlling interest in an entity that owns BC Sorrento. Additionally, the company subleased excess facilities to Avanir Pharmaceuticals.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $100.6 million cash balance against the projected increase in R&D and SG&A expenses for the remainder of 2007 and 2008.
• Revenue Recognition: Confirm the amortization schedule for the $30 million in deferred revenue from Roche and Baxter to understand future revenue visibility.
• Clinical Trial Progress: Monitor the status of the Phase I/IIa clinical trial for Chemophase, as this is the primary driver for future valuation beyond current collaborations.
• Manufacturing Capacity: Assess the capacity and reliability of Avid Bioservices to scale up API production required by the Roche agreement.
• Dilution Impact: Review the terms of outstanding warrants and options to estimate potential dilution if the company calls warrants or raises additional capital.